X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CADILA HEALTHCARE - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CADILA HEALTHCARE SUN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 46.6 24.1 193.1% View Chart
P/BV x 3.8 6.1 62.0% View Chart
Dividend Yield % 0.6 0.8 78.7%  

Financials

 SUN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
CADILA HEALTHCARE
Mar-17
SUN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs842460 183.1%   
Low Rs572305 187.7%   
Sales per share (Unadj.) Rs131.692.1 142.9%  
Earnings per share (Unadj.) Rs32.714.8 220.7%  
Cash flow per share (Unadj.) Rs38.018.5 205.5%  
Dividends per share (Unadj.) Rs3.503.20 109.4%  
Dividend yield (eoy) %0.50.8 59.2%  
Book value per share (Unadj.) Rs152.768.0 224.6%  
Shares outstanding (eoy) m2,399.261,023.74 234.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.44.2 129.4%   
Avg P/E ratio x21.625.8 83.8%  
P/CF ratio (eoy) x18.620.7 90.0%  
Price / Book Value ratio x4.65.6 82.3%  
Dividend payout %10.721.6 49.6%   
Avg Mkt Cap Rs m1,696,877391,581 433.3%   
No. of employees `00017.516.9 103.9%   
Total wages/salary Rs m49,02315,002 326.8%   
Avg. sales/employee Rs Th18,028.35,594.5 322.3%   
Avg. wages/employee Rs Th2,798.8890.1 314.4%   
Avg. net profit/employee Rs Th4,479.5899.9 497.8%   
INCOME DATA
Net Sales Rs m315,78494,295 334.9%  
Other income Rs m6,2321,286 484.6%   
Total revenues Rs m322,01695,581 336.9%   
Gross profit Rs m100,89319,036 530.0%  
Depreciation Rs m12,6483,750 337.3%   
Interest Rs m3,998450 888.4%   
Profit before tax Rs m90,47916,122 561.2%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m12,1161,289 939.9%   
Profit after tax Rs m78,46215,168 517.3%  
Gross profit margin %31.920.2 158.3%  
Effective tax rate %13.48.0 167.5%   
Net profit margin %24.816.1 154.5%  
BALANCE SHEET DATA
Current assets Rs m329,53760,223 547.2%   
Current liabilities Rs m178,87053,058 337.1%   
Net working cap to sales %47.77.6 627.9%  
Current ratio x1.81.1 162.3%  
Inventory Days Days7970 113.1%  
Debtors Days Days8388 94.4%  
Net fixed assets Rs m204,76672,984 280.6%   
Share capital Rs m2,3991,024 234.3%   
"Free" reserves Rs m363,99768,576 530.8%   
Net worth Rs m366,39769,600 526.4%   
Long term debt Rs m14,36124,684 58.2%   
Total assets Rs m614,102152,207 403.5%  
Interest coverage x23.636.8 64.2%   
Debt to equity ratio x00.4 11.1%  
Sales to assets ratio x0.50.6 83.0%   
Return on assets %13.410.3 130.9%  
Return on equity %21.421.8 98.3%  
Return on capital %24.817.9 138.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m44,11821,280 207.3%   
Fx outflow Rs m24,48410,874 225.2%   
Net fx Rs m19,63410,406 188.7%   
CASH FLOW
From Operations Rs m70,82213,495 524.8%  
From Investments Rs m-42,216-29,103 145.1%  
From Financial Activity Rs m-22,85423,158 -98.7%  
Net Cashflow Rs m6,1077,556 80.8%  

Share Holding

Indian Promoters % 63.7 74.8 85.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 8.3 61.8%  
FIIs % 23.0 5.9 389.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 11.0 75.5%  
Shareholders   133,026 44,069 301.9%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   SUVEN LIFE  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  SHASUN PHARMA  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 25, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS